Vermillion Signs on Premiere Source Diagnostics for OVA1 Reimbursement | GenomeWeb

This story originally ran on April 21.

Vermillion this week said it will be working with reimbursement services firm Premiere Source Diagnostics for the OVA1 triage ovarian cancer test.

OVA1 was commercially launched by Vermillion and Quest Diagnostics last month after receiving US Food and Drug Administration clearance last fall. Medicare is also covering the test (PM 03/12/10).

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.